MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

Home・Lista de Ações・Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Fechado

SetorSaúde

74.21 -0.82

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

73.43

Máximo

75.12

Indicadores-chave
By Trading Economics
Rendimento	-100M -229M
Vendas	46M 203M
Margem de lucro	-112.808
Funcionários	1,402
EBITDA	4.7B 4.6B

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+29.95% upside

Dividendos
By Dow Jones
Próximos Ganhos	29 de abr. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-1.7B 12B
Abertura anterior	75.03
Fecho anterior	74.21

Sentimento de Notícias

By Acuity

50%

170 / 349 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Neutral Evidence

29.78 / 33.645 Suporte e Resistência

Ionis Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

6 de abr. de 2026, 23:17 UTC

Ganhos

Samsung Forecasts Record First-Quarter Operating Profit

6 de abr. de 2026, 23:00 UTC

Ações em Alta

Stocks to Watch: Health Insurers, Mawson, Owlet

6 de abr. de 2026, 22:13 UTC

Grandes Movimentos do Mercado

Health Insurance Shares Gain on 2.48% Medicare Rate Bump

6 de abr. de 2026, 21:46 UTC

Aquisições, Fusões, Aquisições de Empresas

BP 'Optimizes Portfolio' and Sells 13 Thorntons Stores to Giant Oil -- OPIS

6 de abr. de 2026, 17:09 UTC

Grandes Movimentos do Mercado

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

6 de abr. de 2026, 16:56 UTC

Notícias Principais

U.S. Released 1.5 Million Bbls of Crude From SPR Last Week, DOE Data Show -- OPIS

6 de abr. de 2026, 14:47 UTC

Grandes Movimentos do Mercado

Stereotaxis Shares Rise on FDA Clearance for Synchrony

7 de abr. de 2026, 00:00 UTC

Notícias Principais

Ukraine's Lesson for Trump: Military Dominance Opens Waterways -- WSJ

6 de abr. de 2026, 23:58 UTC

Conversa de Mercado

Notícias Principais

Iran War Will Keep Oil Prices High Through 2Q, Says Westpac -- Market Talk

6 de abr. de 2026, 23:50 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for Iran Cease-Fire -- Market Talk

6 de abr. de 2026, 23:36 UTC

Conversa de Mercado

Gold Edges Higher as Investors Focus on U.S.-Iran Conflict -- Market Talk

6 de abr. de 2026, 23:15 UTC

Conversa de Mercado

RBA Won't Raise Rates as Australia's Economy Softens Fast -- Market Talk

6 de abr. de 2026, 22:52 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

6 de abr. de 2026, 22:52 UTC

Conversa de Mercado

Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk

6 de abr. de 2026, 22:14 UTC

Conversa de Mercado

Correction to Live Cattle Futures Article

6 de abr. de 2026, 20:56 UTC

Conversa de Mercado

Mexican Private Consumption Fell in January -- Market Talk

6 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Energy & Utilities Roundup: Market Talk

6 de abr. de 2026, 20:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

6 de abr. de 2026, 19:58 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

6 de abr. de 2026, 19:58 UTC

Conversa de Mercado

Live Cattle Futures Hit Record High, Hogs Edge Up -- Market Talk

6 de abr. de 2026, 19:11 UTC

Conversa de Mercado

U.S. Natural Gas Edges Up in Rangebound Trade -- Market Talk

6 de abr. de 2026, 19:06 UTC

Conversa de Mercado

Treasury Yields Decline as a Belligerent Trump Talks to Reporters -- Market Talk

6 de abr. de 2026, 19:03 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

6 de abr. de 2026, 19:03 UTC

Conversa de Mercado

Crude Futures Edge Up As Trump's Iran Deadline Nears -- Market Talk

6 de abr. de 2026, 18:36 UTC

Aquisições, Fusões, Aquisições de Empresas

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6 de abr. de 2026, 17:59 UTC

Conversa de Mercado

Notícias Principais

Travel Booking Companies Facing More Demand Uncertainty Than Expected -- Market Talk

6 de abr. de 2026, 17:13 UTC

Aquisições, Fusões, Aquisições de Empresas

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6 de abr. de 2026, 16:33 UTC

Conversa de Mercado

Oil Futures Steady as Market Awaits Trump -- Market Talk

6 de abr. de 2026, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

6 de abr. de 2026, 14:59 UTC

Ganhos

Strategy Records a $14.5 Billion Unrealized Loss in First Quarter -- WSJ

Comparação entre Pares

Variação de preço

Ionis Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

29.95% parte superior

Previsão para 12 meses

Média 97.19 USD 29.95%

Máximo 120 USD

Mínimo 72 USD

Com base em 14 analistas de Wall Street que oferecem metas de preço de 12 meses para Ionis Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

14 ratings

Comprar

Manter

Vender

Com base em 14 analistas que deram avaliações de ações para Ionis Pharmaceuticals Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

29.78 / 33.645Suporte e Resistência

The bullish and bearish events are balanced.

All events are bullish.

All events are bearish.

Sentimento

By Acuity

170 / 349 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.